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Background: The influence of family history (FH) on cancer recurrence and survival among patients with established colorectal cancer 
(CRC) remains uncertain. This study aimed to evaluate the association of FH with cancer recurrence, survival, and the incidence of colorectal 
adenomas in patients with CRC.
Methods: Consecutive patients with stage III CRC diagnosed between 2004 and 2009 and followed-up in Severance Hospital were 
retrospectively enrolled and followed until December 2014. Overall survival (OS) and disease-free survival (DFS) according to FH of CRC 
or colorectal neoplasm were evaluated using Cox proportional hazards regression and Kaplan–Meier curve. 
Results: Among analyzed 979 patients, 69 (7.0%) was identified as having a FH of CRC in a first-degree relative. During a median 
follow-up of 9.6 years, mortality occurred in 14 of 69 patients (20.3%) with a FH of CRC and 348 of 910 patients (38.2%) without 
a FH. Compared with patients without a FH, a first-degree FH of CRC, first or second-degree FH of CRC, and first-degree FH of colorectal 
neoplasm (CRC or polyps) were associated with a significant reduction in the risk of overall mortality, with adjusted hazard ratios (HRs) 
of 0.52 (95% CI, 0.29-0.92), 0.51 (95% CI, 0.30-0.88), and 0.48 (95% CI, 0.28-0.82), respectively. However, DFS improvement was 
significant only when the definition of FH was FH of colorectal neoplasm (adjusted HR 0.57; 95% CI, 0.36-0.89). The incidence of adenoma 
and advanced adenoma was not different according to the FH.
Conclusions: Among patients with stage III CRC receiving curative surgery, a FH of colorectal neoplasm was associated with a reduction 
in cancer recurrence and mortality. The larger scaled studies are needed.
(J Cancer Prev 2019;24:1-10)
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INTRODUCTION
Approximately 5% to 10% of colorectal cancer (CRC) patients 
have at least one affected first-degree relative (FDR) with CRC 
[1,2]. Having a family history (FH) of CRC in a FDR is a known risk 
factor for the development of CRC, with twofold increased 
lifetime risk of CRC [3-5]. This risk increases with a greater 
number or younger age at diagnosis of the affected FDRs [6-8]. 
Based on this, current screening recommendations for CRC 
adopted the number and age at diagnosis above or below 60 years 
of affected FDR with CRC or an advanced adenoma as risk 
stratifiers [9].
However, the influence of FH of CRC on CRC recurrence and 
survival remains uncertain, and the results from studies are 
inconsistent. Several studies reported the negligible impact of FH 
of CRC and survival [10-12]. Some studies reported improved 
survival [13-16], whereas the others showed worse prognosis in 
patients with a FH of CRC [17,18]. This inconsistency may be 
attributed to different study designs, heterogeneity in baseline 
CRC characteristics and study population, or different definition 
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of FH. The definition of FH among patients with CRC can vary, 
from including only FDR with CRC to encompassing second- or 
third-degree relatives with CRC or adenomas. These various 
definitions of FH were not applied or compared in previous 
studies evaluating outcome in CRC patients with FH, and it is 
unknown which definition has the largest association with the 
prognosis. 
A FH of CRC is often the cause of shorter colonoscopy 
surveillance interval, although the rationale is insufficient [19]. 
The influence of FH on the recurrence or survival of CRC has been 
studied, but no study has evaluated the impact of FH on the 
incidence of colorectal adenomas on follow-up surveillance 
colonoscopy in patients with previous CRC. One study showed 
that individuals with an FH of FDR with CRC were more likely to 
have a recurrence of adenomas, but this was not statistically 
significant [20]. Currently it is unknown whether a FH of CRC 
would impact the natural history of adenoma, especially in 
patients with previous CRC, and whether consideration of 
shorter surveillance interval is needed in patients with previous 
CRC and FH. 
The aim of our study was to evaluate the association of FH of 
CRC with cancer recurrence, survival, and the incidence of 
colorectal adenomas in patients with stage III CRC through the 
use of a various definitions of FH and more homogenous Asian 
patients.
MATERIALS AND METHODS
1. Study population
Consecutive patients with stage III CRC diagnosed between 
2004 and 2009 and followed-up in Severance Hospital were 
retrospectively enrolled and followed until October 2018. 
Exclusion criteria were incomplete records including FH, not 
receiving curative surgery, patients with known familial 
adenomatous polyposis or hereditary nonpolyposis CRC 
(HNPCC), and inflammatory bowel disease. 
The study protocol was in accordance with the ethics guidelines 
of the 1975 Declaration of Helsinki and the study procedure was 
approved by the Institutional Review Board of Severance Hospital. 
2. Data collection and family history assessment
Demographics and medical history, FH of CRC or adenoma 
were obtained by medical chart review. Multiple medical records 
containing FH status such as admission note, intern note, nurse 
chart, and colonoscopy results were reviewed. Survival or death, 
along with the cause of death was confirmed by data from 
National Cancer Registry. We used three different definitions of 
FH: 1) first-degree FH of CRC, which was defined as having at least 
one FDR (parent, sibling, or offspring) with CRC; 2) first or 
second-degree FH of CRC, which was defined as having at least 
one first-degree or second-degree relative with CRC; 3) 
first-degree FH of colorectal neoplasm (CRC or polyps), which is 
defined as having at least one FDR with CRC or colorectal polyps. 
3. Colonoscopic surveillance
All patients received a baseline colonoscopy before curative 
surgery or within 6 months after the surgery (in cases of 
obstructing CRCs). We excised all adenomas detected during 
baseline colonoscopy. The incidence of colorectal adenoma and 
advanced adenoma in each surveillance colonoscopy and during 
total follow-up period was evaluated. An advanced adenoma was 
defined as an adenoma 10 mm or greater in diameter, an adenoma 
with villous component, or with high-grade dysplasia or 
carcinoma. 
4. Survival analysis
The endpoints were overall survival (OS), disease-free survival 
(DFS), and colorectal adenoma incidence rate on each 
surveillance colonoscopy. OS was defined as the time from initial 
curative surgery to death as a result of any cause. DFS was defined 
as the time from initial curative surgery to tumor recurrence, 
occurrence of a new primary CRC, or death from any cause. 
Colorectal adenoma incidence rate was defined as the number of 
patients with adenoma in surveillance colonoscopy divided by 
total number of patients with surveillance colonoscopy. 
5. Statistical analysis
Baseline patient characteristics were analyzed with descriptive 
statistics. Comparisons of demographic, clinical, and pathologic 
variables according to the FH were done using Student’s t-test for 
continuous variables and Pearson’s 2 test for categorical 
variables. The survival analysis was done using Kaplan–Meier 
curves and the log-rank test. Cox proportional hazards regression 
was used to determine the simultaneous impact of FH and 
potential confounders on OS and DFS. Tests of interactions 
between FH and potentially modifying covariates were assessed 
by entering the cross product of FH and the covariate of interest. 
A logistic regression analysis was used to evaluate the colorectal 
adenoma incidence rate with adjustment for various confounders. 
A value of P ＜ 0.05 was considered significant. All statistical 
analyses were conducted using IBM SPSS ver. 20.0 (IBM Corp., 
Armonk, NY, USA).
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Figure 1. Flowchart of the study. CRC, colorectal cancer; HNPCC, 
hereditary nonpolyposis CRC; FAP, familial adenomatous polyposis.
Table 1. Baseline characteristics by family history of colorectal cancer
Characteristic
First-degree family history 
of colorectal cancer P-value
No (n = 910) Yes (n = 69)
Age (yr) 59.7 (14-90) 57.5 (34-75) 0.14
Sex (male) 557 (61.2) 37 (53.6) 0.21
Body mass index (kg/m2) 23.5 (15.8-37.0) 23.5 (17.7-31.0) 0.29
ECOG PS 0.21
0 749 (79.5) 54 (77.1)
1-2 193 (20.5) 16 (22.9)
Current smoking 133 (14.6) 12 (17.4) 0.53
Alcohol 0.71
None 601 (66.3) 45 (65.2)
＜ 1 drink/d 249 (27.5) 18 (26.1)
≥ 1 drink/d 56 (6.2) 6 (8.7)
Site of primary tumor 0.23
Right colon 194 (21.3) 19 (27.5)
Left colon and rectum 716 (78.7) 50 (72.5)
Preoperative CEA (ng/mL) 3.00 (0-259) 2.00 (0-294) 0.61
Depth of invasion through bowel wall 0.15
T1 and T2 105 (11.5) 12 (17.4)
T3 and T4 805 (88.5) 57 (82.6)
Positive lymph nodes 0.25
1-3 611 (67.1) 51 (73.9)
≥ 4 299 (32.9) 18 (26.1)
Tumor differentiation 0.86
Well 89 (9.8) 7 (10.1)
Moderate 730 (80.2) 54 (78.3)
Poor 53 (5.8) 4 (5.8)
Other 38 (4.2) 4 (5.8)
MSI status 0.08
MSS 756 (92.6) 55 (85.9)
MSI-L 34 (4.2) 4 (6.2)
MSI-H 26 (3.2) 5 (7.8)
Values are presented as median (range) or number (%). ECOG, 
Eastern Cooperative Oncology Group; PS, performance status; CEA, 
carcinoembryonic antigen; MSI, microsatellite instability; MSS, mi-
crosatellite stable; MSI-L, MSI-low; MSI-H, MSI-high.
RESULTS
1. Baseline and follow-up characteristics
Figure 1 shows a flowchart of the study. Of 1,001 consecutive 
patients with stage III CRC diagnosed between 2004 and 2009 and 
followed-up in Severance Hospital, 979 patients were included in 
analysis. Baseline characteristics for the 979 patients are 
presented in Table 1. Among analyzed 979 patients, 69 (7.0%) was 
identified as having a FH of CRC in at least one FDR. A total of 79 
(8.1%) had a FH of CRC in at least one FDR or second-degree 
relative, and 87 (8.9%) had at least one FDR with CRC or colorectal 
polyps. The baseline characteristics and potentially prognostic 
patient and tumor characteristics were not different according to 
FH. Microsatellite instability (MSI) measurement was performed 
in 880 (89.9%) of 979 patients, and the results were not different 
according to the FH (Table 1).
The median follow-up time from curative surgery was 9.6 years 
(interquartile range, 4.9-10.9 years). Mortality occurred in 14 of 69 
patients (20.3%) with a FH of CRC in at least one FDR and 348 of 
910 patients (38.2%) without a FH. 
2. Survival analysis 
A FH of CRC was associated with a significant reduction in the 
risk of cancer recurrence or overall mortality (Fig. 2 and 3). This 
improvement in OS and DFS was consistent among different 
definitions of FH, and this relationship remained largely 
unchanged after adjusting for other predictors of survival (Table 
2 and 3). The results from univariate and multivariate Cox 
regression analyses of predictors of OS and DFS are shown in 
Table 2. Along with age at diagnosis (hazard ratio [HR] 1.03; 95% 
CI, 1.02-1.04), performance status (HR 1.48; 95% CI, 1.16-1.90), 
number of positive lymph nodes (HR 1.64; 95% CI, 1.31-2.06) and 
adjuvant chemotherapy (HR 0.67; 95% CI, 0.49-0.93), FH of 
colorectal neoplasm was independent favorable predictor for OS 
(multivariable adjusted HR 0.49; 95% CI, 0.28-0.83). The adjusted 
HR was 0.52 (95% CI, 0.29-0.92) and 0.51 (95% CI, 0.30-0.88) when 
using the definition of  FH of ‘CRC in FDR’ and ‘CRC in FDR or 
second-degree relative’, respectively. However, the adjusted HR 
for cancer recurrence or death (i.e., DFS) was significant only 
when the definition of FH was ‘colorectal neoplasm in FDR’ (HR 
of 0.57; 95% CI, 0.36-0.89). 
We also assessed the association between FH and OS or DFS 
according to the strata of other potential predictors of outcome 
(Fig. 4). Because FH definition of ‘colorectal neoplasm in FDR’ was 
consistently significant predictor for both OS and DFS, we used 
this definition of FH in stratified analysis. The effect of FH on the 
risk of cancer recurrence or death was not significantly modified 
by gender or performance status. In contrast, the effect of FH was 
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Figure 2. Overall survival according to the different definitions of family history in stage III colorectal cancer (n = 979). (A) Overall survival 
according to 1st-degree family history of colorectal cancer. (B) Overall survival according to 1st or 2nd degree family history of colorectal 
cancer. (C) Overall survival according to 1st-degree family history of colorectal cancer or polyp.
Figure 3. Disease-free survival according to the different definitions of family history in stage III colorectal cancer (n = 979). (A) Disease-free 
survival according to 1st-degree family history of colorectal cancer. (B) Disease-free survival according to 1st or 2nd degree family history of 
colorectal cancer. (C) Disease-free survival according to 1st-degree family history of colorectal cancer or polyp.
different according to patient age, depth of invasion, number of 
positive lymph nodes, tumor location, differentiation, and MSI 
status. The protective effect of FH of colorectal neoplasm on 
cancer recurrence or mortality was prominent among patients 
older than 50 years, T3 or T4 disease, positive lymph node of less 
than 4, tumor location at left colon (splenic flexure to the 
rectosigmoid junction) and rectum, well to moderate 
differentiation, and microsatellite stable (MSS) tumor. However, 
a test of interaction between these factors and the presence of FH 
revealed that the effect of FH on OS and DFS did not appear to be 
modified by these factors (all P for interaction ＞ 0.05) (Fig. 4).
3. Colonoscopic surveillance and findings of 
follow-up colonoscopy
Among the 637 patients underwent follow-up colonoscopy in 
our hospital, 226 (35.5%), 360 (56.5%), and 51 patients (8.0%) 
underwent follow-up colonoscopy once, twice, and more than 
three times, respectively. More follow-up colonoscopies were 
done in patients with FH with colorectal neoplasm than patients 
without FH (P < 0.01). Also, the interval to the first follow-up 
colonoscopy was slightly shorter in patients with FH (13.8 mo vs. 
13.4 mo, P = 0.03) (Table 4). The incidence of adenoma and 
advanced adenoma in each follow-up colonoscopy and during 
entire follow-up was evaluated. There was no difference in 
detection of total adenoma or advanced adenoma in subjects with 
FH compared to those without FH (OR 1.27 and 1.33, all P ＞ 0.05) 
(Table 5). This was unchanged after adjustment for potential 
factors related to the adenoma and advanced adenoma incidence, 
including age, gender, BMI, number of follow-up colonoscopies, 
MSI status, aspirin use, metformin use, interval to first follow-up 
colonoscopy, and chemotherapy (Supplementary Table S1). For 
advanced adenoma, MSI was related to the incidence of advanced 
adenoma (adjusted OR 3.34; 95% CI, 1.31-8.53). 
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Table 2. Univariate and multivariate analysis for overall survival and disease-free survival in patients with stage III colorectal cancer
Characteristic
Univariate analysis Multivariate
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Overall survival
1st-degree family history of CRCa 0.48 0.28-0.82 < 0.01 0.52 0.29-0.92 0.03
1st or 2nd-degree family history of CRCa 0.47 0.28-0.77 < 0.01 0.51 0.30-0.88 0.02
1st-degree family history of colorectal neoplasma 0.42 0.26-0.70 < 0.01 0.48 0.28-0.82 0.01
Age 1.04 1.03-1.05 < 0.01 1.03 1.02-1.04 < 0.01
Male sex 1.22 0.98-1.51 0.08
BMI 0.96 0.93-0.99 0.01 0.97 0.94-1.01 0.14
Current smoking 1.16 0.88-1.53 0.30
Alcohol 0.35
None 1
＜ 1 drink/d 0.86 0.68-1.10 0.22
≥ 1 drink/d 0.86 0.55-1.34 0.50
Performance status (0 vs. 1-2) 1.58 1.25-1.99 < 0.01 1.48 1.16-1.90 < 0.01
Depth of invasion (T1 and T2 vs. T3 and T4) 1.49 1.04-2.14 0.03 1.26 0.88-1.81 0.22
Positive lymph nodes (1-3 vs. ≥ 4) 1.70 1.38-2.10 < 0.01 1.64 1.31-2.06 < 0.01
Right colon 1.07 0.84-1.38 0.58
Preoperative CEA 1.00 1.00-1.01 0.12
Poor differentiation 1.63 1.01-2.41 0.02 1.47 0.98-2.19 0.06
MSI status 0.29
MSS 1
MSI-L 1.06 0.62-1.81 0.831
MSI-H 0.49 0.22-1.10 0.09
Adjuvant chemotherapy 0.54 0.41-0.72 < 0.01 0.67 0.49-0.93 0.02
Disease-free survival
1st-degree family history of CRCa 0.59 0.38-0.92 0.02 0.68 0.42-1.09 0.11
1st or 2nd-degree family history of CRCa 0.56 0.37-0.85 0.01 0.65 0.41-1.02 0.65
1st-degree family history of colorectal neoplasma 0.49 0.33-0.75 < 0.01 0.57 0.36-0.89 < 0.01
Age 1.02 1.02-1.03 < 0.01 1.02 1.01-1.03 < 0.01
Male sex 1.20 0.99-1.46 0.06
BMI 0.97 0.94-1.00 0.04 0.97 0.94-1.00 0.09
Current smoking 1.23 0.95-1.57 0.11
Alcohol 0.83
None 1
＜ 1 drink/d 0.99 0.80-1.23 0.96
≥ 1 drink/d 0.88 0.59-1.32 0.54
Performance status (0 vs. 1-2) 1.50 1.21-1.86 < 0.01 1.36 1.07-1.72 < 0.01
Depth of invasion (T1 and T2 vs. T3 and T4) 1.67 1.20-2.32 < 0.01 1.39 0.97-1.99 0.07
Positive lymph nodes (1-3 vs. ≥ 4) 1.67 1.38-2.02 < 0.01 1.52 1.22-1.88 < 0.01
Right colon 1.02 0.81-1.28 0.90
Preoperative CEA 1.00 1.00-1.01 0.04 1.01 1.00-1.01 < 0.01
Poor differentiation 1.74 1.23-2.47 < 0.01 1.91 1.31-2.77 < 0.01
MSI status 0.17
MSS 1
MSI-L 0.90 0.54-1.52 0.70
MSI-H 0.51 0.25-1.03 0.06
Adjuvant chemotherapy 0.73 0.55-0.97 0.03 0.91 0.65-1.29 0.61
CRC, colorectal cancer; BMI, body mass index; CEA, carcinoembryonic antigen; MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, 
MSI-low; MSI-H, MSI-high. aEach different definition of family history was included in mutivariate analysis separately. Among three separate 
multivariate analyses according to the different definitions of family history, hazard ratios and P-values with ‘1st-degree family history of 
colorectal neoplasm’ were expressed.
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Figure 4. Stratified analysis of overall survival (A) and disease-free survival (B) according to the 1st-degree family history of colorectal neoplasm. 
MSI, microsatellite instability; MSS, microsatellite stable.
Table 3. Unadjusted and multivariate adjusted hazard ratios for overall survival and disease-free survival according to presence of family 
member with colorectal neoplasm
Variable
1st-degree FH of CRC 1st or 2nd-degree FH of CRC 1st-degree FH of colorectal neoplasm
No Yes No Yes No Yes
Overall mortality
No. of events 348 14 346 16 346 16
No. at risk 910 69 900 79 892 87
Unadjusted HR (95% CI) 1 0.48 (0.28-0.82) 1 0.47 (0.28-0.77) 1 0.42 (0.26-0.70)
Adjusted HR (95% CI) 1 0.52 (0.29-0.92) 1 0.59 (0.32-1.07) 1 0.49 (0.28-0.83)
Cancer recurrence or death from any cause (disease-free survival)
No. of events 419 21 417 23 417 23
No. at risk 910 69 900 79 892 87
Unadjusted HR (95% CI) 1 0.59 (0.38-0.92) 1 0.56 (0.37-0.85) 1 0.49 (0.33-0.75)
Adjusted HR (95% CI) 1 0.68 (0.42-1.09) 1 0.65 (0.41-1.02) 1 0.57 (0.36-0.91)
FH, family history; CRC, colorectal cancer; HR, hazard ratio.
DISCUSSION
In the present study, a FH of colorectal neoplasm in FDR was 
associated with a significant reduction in cancer recurrence and 
mortality in a cohort of patients with stage III CRC treated with 
surgery. This improvement in OS and DFS was consistent among 
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Figure 4. Continued.
Table 4. Comparison of total number and interval of follow-up co-
lonoscopies between the patients with and without family history 
of colorectal neoplasm
　No family history 
(n = 565)
Family history 
(n = 72)
P-value
No. of follow-up colonoscopies 0.01
1 210 (37.2) 16 (22.2)
2 315 (55.8) 45 (62.5)
≥ 3  40 (7.1) 11 (15.3) 　
Interval to follow-up colonoscopy (mo)
1st 13.8 (3.6-93.9) 13.4 (3.8-40.7) 0.03
2nd 48 (17-72) 48 (23-59) 0.41
3rd 81 (36-110) 78 (51-94) 0.57
Values are presented as number (%) or median (range).
different definitions of FH, but the adjusted HR for cancer 
recurrence or death was significant only when the definition of 
FH was ‘colorectal neoplasm in FDR’. The incidence of adenoma 
and advanced adenoma during surveillance colonoscopy was not 
different according to the FH. 
The originality of this study is as follows. First, we addressed 
the influence of FH on the prognosis of patients with CRC using 
various definitions of FH, and found that the FH of colorectal 
neoplasm including CRC and polyps is associated with reduced 
recurrence and mortality of CRC. Second, we evaluated whether a 
FH of colorectal neoplasm would impact the natural history of 
adenoma in patients with previous CRC and found that the 
incidence of adenomas and advanced adenomas was not 
different according to the FH of colorectal neoplasm in patients 
with CRC. 
The definition of FH among patients with CRC can vary, and 
most studies define the FH as ‘FH of CRC in FDR’ with or without 
including second-degree relatives. Whether the FH of colorectal 
neoplasm including polyps in FDR affects the prognosis of 
patients with CRC is unknown. In this study, FH of not only CRC 
but also polyps in FDR had association with prognosis in patients 
with CRC. Although this finding needs to be confirmed by further 
studies, more detailed history taking including FH of colorectal 
polyps may be helpful in prognostication of CRC patients. 
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Table 5. Comparison of the incidence rates of adenoma and advanced adenoma on each follow-up colonoscopy between the patients with 
and without family history of colorectal neoplasm
Follow-up colonoscopy No family history (n = 565) Family history (n = 72) OR 95% CI P-value
1st
Adenoma incidence 130/565 (23.0) 17/72 (23.6) 1.41 0.85-2.34 0.19
Advanced adenoma incidence 22/565 (3.9) 2/72 (2.8) 1.18 0.27-5.12 0.82
2nd
Adenoma incidence 80/355 (22.5) 13/56 (23.2) 0.89 0.49-1.59 0.68
Advanced adenoma incidence 8/355 (2.3) 2/56 (3.6) 1.46 0.31-6.87 0.63
3rd
Adenoma incidence 13/40 (32.5) 5/10 (50.0) 2.94 0.97-8.91 0.06
Advanced adenoma incidence 2/40 (5.0) 1/10 (10.0) 2.91 0.26-32.65 0.39
Total 
Total adenoma 181 (32.0) 27 (37.5) 1.27 0.76-2.11 0.36
Advanced adenoma 30 (5.3) 5 (6.9) 1.33 0.50-3.54 0.57
Values are presented as number (%). OR, odds ratio.
We observed an increase in surveillance colonoscopy among 
those with a FH. Nevertheless, the incidence of adenoma and 
advanced adenoma was not increased in the patients with CRC 
having FH of colorectal neoplasm. It is unknown whether a FH of 
CRC would impact the natural history of adenoma, especially in 
patients with previous CRC, but the need for more frequent 
surveillance colonoscopy in patients with previous CRC and FH 
has been a concern of many clinicians. In the clinical practice, a 
FH of CRC is often the cause of shorter colonoscopy surveillance 
interval, although the rationale is insufficient [19].  Although 
more results from prospective studies are needed, it is unlikely 
that more frequent colonoscopy will be helpful in CRC patients 
with FH of colorectal neoplasm, based on the results of our study. 
The effect of FH on improved prognosis of CRC is sometimes 
explained by earlier detection of CRC. However, our study only 
included the patients with same stage, and the baseline patient, 
disease, and therapeutic factors associated with CRC prognosis 
such as performance status, depth of invasion, the number of 
positive lymph nodes, differentiation, preoperative carcino-
embryonic antigen, and adjuvant chemotherapy were not 
different between patients with and without FH. Also, the effect 
of FH persisted after adjusting for these factors. The protective 
effect of FH of colorectal neoplasm on cancer recurrence or 
mortality in this study was modified by age, depth of invasion, 
number of positive lymph nodes, tumor location, differentiation, 
and MSI status. Although tests for interaction were not 
significant, these factors have a potential to be a mechanism by 
which FH affects outcome.
Up to 30% of CRCs exhibit increased familial risk, but only 
approximately 5% of CRCs are associated with highly penetrant, 
well-defined inherited mutations and clinical presentation, and 
the etiologies of the remaining 20% to 30% of inherited CRCs are 
not completely understood. Relatively common but less penetrant 
genetic predisposition may influence survival as well as 
increased CRC risk in familial CRC patients. Some previous 
studies suggested that FH of CRC is associated with higher 
frequency of MSI-high [21],  and the beneficial effect of FH on CRC 
survival was prominent in right colon [12,15,16]. However, the 
association of MSI status on prognosis was not consistent 
between studies [14],  and MSI status was not different by FH in 
our study. Rather, in this study, stratified analysis showed that 
the improved OS and DFS was more prominent among patients 
with left-sided colon and rectal cancer and MSS cancer. Although 
left side predominance was one of the unique characteristics of 
Asian HNPCC patients [22], our result suggests that the possible 
association between a FH and improved prognosis may be 
attributed to unrevealed genetic predisposition rather than MSI 
or MMR status. The linkage analysis and population-based 
genome-wide association studies have identified a number of 
potential loci associated with familial CRC, such as 9q22, 8q23, 
8q24, 9p24, 11q23, and 18q21 [23,24]. The association of these 
genetic predisposition and CRC outcome needs to be studied 
further. However, the relationship between FH and prognosis of 
CRC is likely to be complex and may be influenced by an 
interaction between genetic predispositions and shared 
environmental factors. Also, it is possible that the mechanism of 
the influence of FH on CRC prognosis is different among Asian 
and Western populations. Further studies are warranted to 
identify the influence of FH on prognosis of CRC and underlying 
mechanism of increased familial risk and possible improved 
survival of CRC. 
Our study has several strengths. First, because we included 
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patients with stage III CRC, the impact of heterogeneity by disease 
stage can be reduced. Second, long-term follow-up for the survival 
was available using central data from National Cancer Registry. 
Third, multiple confounding factors of mortality or adenoma 
incidence such as smoking, alcohol, BMI, use of aspirin were 
evaluated and adjusted. Fourth, because the majority of the 
patients examined the MSI status, the association between MSI 
status and prognosis could be evaluated.
There were several limitations of this study. First, we collected 
self-reported FH on medical records retrospectively, and FH 
status may be misclassified or underestimated. Indeed, the 
sample size of CRC patients with FH of colorectal neoplasm in this 
study was 8.9%, less than some other studies. However, the Asian 
studies reported relatively small proportion of FH compared with 
Western studies [25,26], and this may be related to the lower 
incidence of CRC in Asia during previous several decades. Also, 
self-reported data have been shown to be reliable in the previous 
studies [27]. To minimize the bias from the self-reported system, 
we collected multiple medical records containing FH status in the 
same subject such as admission note, intern note, nurse chart, 
and colonoscopy results. Second, though we analyzed MSI status, 
we were unable to evaluate for the other detailed genetic 
information. Because techniques for genetic analysis including 
next generation sequencing are developed, it is expected that 
these tests will be used to link the genes and prognosis related to 
FH in the near future. Third, this study was a single center, 
retrospective study, which might lead to bias especially for the 
surveillance colonoscopy which showed variable number and 
interval among individuals. 
In conclusion, a FH of colorectal neoplasm including CRC and 
polyps in FDR was associated with a significant reduction in 
cancer recurrence and mortality in a cohort of patients with stage 
III CRC treated with surgery. The incidence of adenoma and 
advanced adenoma on surveillance colonoscopy was not 
different according to the FH of colorectal neoplasm in patients 
with CRC. The protective effect of FH of colorectal neoplasm on 
cancer recurrence or mortality was modified by age, depth of 
invasion, number of positive lymph nodes, tumor location, 
differentiation, and MSI status. The association between a FH 
and improved prognosis may be attributed to unrevealed genetic 
predisposition which might have association with these 
modifying factors. Further studies are warranted to identify the 
underlying mechanism of increased familial risk and possible 
association with improved outcome of CRC across different 
populations. 
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